Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.
about
Carcinoma ex pleomorphic adenoma: case report and options for systemic therapyHER2 in solid tumors: more than 10 years under the microscope; where are we now?Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases.Carcinoma ex pleomorphic adenoma of the parotid gland: a multi-institutional retrospective analysis in the Northern Japan Head and Neck Cancer Society.Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.Outcomes and prognostic factors for surgery followed by modern radiation therapy in parotid gland carcinomas.Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.The dream and reality of histology agnostic cancer clinical trials.Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas.Increased risk of salivary gland cancer among women with a previous cancer diagnosis.
P2860
Q33840219-8F4ED70A-5D71-490A-9F81-452011501A1AQ35211263-A10EC353-66B3-4947-9D14-2467E92A5000Q35230643-D3B28564-EDBB-4C33-A384-908A049A74E1Q38841254-8251F0C4-94BA-4876-8A52-EE4263C0D77DQ38863519-473BCBCD-A7CD-4641-9050-1B8B626473B6Q39831543-85B76703-3D33-4E30-8222-E60BA6DD5036Q40693954-8B7EF3AA-7E5D-4EDF-B49B-114C8D926273Q41906973-830892DB-8E1F-4273-85B6-C00FCE71E39DQ42337532-56BF39B7-A584-4A7E-B08C-2A5D36D30FA6Q45408645-4D6683F0-C387-484C-92D7-3BB980533A50Q48123633-4DB3322B-730B-49DB-A830-633BDFE6682CQ50675747-A53B527D-F043-46D7-AED3-81614DE0A230Q51064222-67C2BB8D-0A38-4B86-A357-F177C246A382
P2860
Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@en
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@nl
type
label
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@en
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@nl
prefLabel
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@en
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@nl
P2093
P2860
P356
P1476
Complete Response to Trastuzum ...... cinoma ex Pleomorphic Adenoma.
@en
P2093
Azusa Komori
Chihiro Kondoh
Hitoshi Hirakawa
Shigenori Kadowaki
Yasuhisa Hasegawa
P2860
P304
P356
10.1159/000355219
P577
2013-09-10T00:00:00Z